These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 868807)

  • 21. [Fibrin x fibrinogen degradation products (FDP)].
    Mori Y; Wada H
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():604-7. PubMed ID: 15658401
    [No Abstract]   [Full Text] [Related]  

  • 22. A latex immunoassay of fibrin/fibrinogen degradation products in plasma using a monoclonal antibody.
    Mirshahi M; Soria J; Soria C; Perrot JY; Boucheix C
    Thromb Res; 1986 Dec; 44(6):715-28. PubMed ID: 3798417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of kits for the detection of fibrin(ogen) degradation products in dogs.
    Stokol T; Brooks M; Erb H; Mauldin GE
    J Vet Intern Med; 1999; 13(5):478-84. PubMed ID: 10499733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
    Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
    Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quantitative evaluation of fibrinogen-fibrin degradation products (FDP) in the blood of full-term newborn infants, using the staphylococcal clumping test].
    Schettini F; Altomare M; Mautone A
    Boll Soc Ital Biol Sper; 1976 Feb; 52(3):121-6. PubMed ID: 949391
    [No Abstract]   [Full Text] [Related]  

  • 26. False-positive D-dimer result in a patient with Castleman disease.
    Mugler K; Lefkowitz JB
    Arch Pathol Lab Med; 2004 Mar; 128(3):328-31. PubMed ID: 14987152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of results of fibrinogen degradation products (FDP) determination by immunologic methods and the results of other studies of the blood clotting system].
    Palester-Chlebowczyk M; Vertun B; Strzyźewska E; Królikiewicz K
    Pol Arch Med Wewn; 1977 Sep; 58(3):247-56. PubMed ID: 928163
    [No Abstract]   [Full Text] [Related]  

  • 28. [Measurement of FDP-D-dimer in DIC and pre-DIC].
    Takagi M; Wada H; Tanigawa M; Iwasaki E; Deguchi A; Mori Y; Suzuki H; Ohkubo I; Endou T; Deguchi K
    Rinsho Byori; 1990 Jul; 38(7):806-12. PubMed ID: 2205744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [FDP and paracoagulation test].
    Matsuda T
    Nihon Rinsho; 1979 Jun; Suppl():2236-7. PubMed ID: 491117
    [No Abstract]   [Full Text] [Related]  

  • 30. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tanned red cell haemagglutination-inhibition immunoassay of fibrinogen-fibrin degradation products.
    Kings GL; Stoodley KD
    Med Lab Sci; 1980 Oct; 37(4):317-22. PubMed ID: 7207041
    [No Abstract]   [Full Text] [Related]  

  • 32. [FDP-E--quantitative analysis by LPIA (latex photometric immunoassay) method].
    Furusaki F; Sudo T; Tsutsui S
    Rinsho Byori; 1989 Apr; Spec No 81():168-75. PubMed ID: 2754804
    [No Abstract]   [Full Text] [Related]  

  • 33. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products.
    Madoiwa S; Kitajima I; Ohmori T; Sakata Y; Mimuro J
    Thromb Res; 2013 Oct; 132(4):457-64. PubMed ID: 24011388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and possible reasons for discordant results between positive FDP and negative D-dimer latex assays in clinical specimens.
    Song KS; Kim YA; Kim HK; Park Q
    Yonsei Med J; 1999 Apr; 40(2):107-11. PubMed ID: 10333712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of FDP and D-dimer for the diagnosis of DIC].
    Kaneko T; Wada H
    Rinsho Byori; 2011 Feb; Suppl 147():79-83. PubMed ID: 21761753
    [No Abstract]   [Full Text] [Related]  

  • 36. The detection of fibrinogen-fibrin degradation products by means of a new antibody-coated latex particle.
    Garvey MB; Black JM
    J Clin Pathol; 1972 Aug; 25(8):680-2. PubMed ID: 5076802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prototype quantitative assay for fibrinogen/fibrin degradation products. Clinical evaluation.
    Sigal SH; Cembrowski GS; Shattil SJ; Brown NM; Schifreen RS; Schwartz MW
    Arch Intern Med; 1987 Oct; 147(10):1790-3. PubMed ID: 3662708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Assay of products of fibrin and fibrinogen degradation in disseminated intravascular coagulations. Evaluation of a new technique].
    Borschneck C; Dreyfus M; Bridey F; Edouard D; Meyer D
    Presse Med; 1995 May 6-13; 24(17):799-802. PubMed ID: 7630868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High fibrin/fibrinogen degradation product to fibrinogen ratio is associated with 28-day mortality and massive transfusion in severe trauma.
    Lee DH; Lee BK; Noh SM; Cho YS
    Eur J Trauma Emerg Surg; 2018 Apr; 44(2):291-298. PubMed ID: 28921171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of urinary and circulating FDP subfragments and subunits: application of the western-blot technique.
    Takahashi S; Noguchi Y; Kitagawa T
    Acta Paediatr Jpn; 1989 Apr; 31(2):127-35. PubMed ID: 2516692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.